SCHEMBL4969975

SCHEMBL4969975

CCCCOc1cc(CCC(=O)OC)ccc1-c1cccc(CN(C)C(=O)c2ccc(OC)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 4/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
PDK1 Q15118 4/20 0.42
LIMK2 P53671 1/20 0.41
FFAR1 O14842 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B1 P14061 1/20 0.40
NLRP3 Q96P20 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970326 0.96 HSD17B2 (0.46) HSD17B2MEN1KMT2ALIMK2FFAR1
SCHEMBL4968524 0.94 HSD17B2 (0.44) HSD17B2MEN1KMT2AFFAR1HSD17B1
SCHEMBL4968914 0.93 HSD17B2 (0.48) HSD17B2MEN1KMT2APOLBHPGD
SCHEMBL4970090 0.93 FFAR1 (0.49) HSD17B2MEN1KMT2APOLBHPGD
SCHEMBL4970767 0.93 KMT2A (0.42) HSD17B2MEN1KMT2AFFAR1HSD17B1
SCHEMBL4971306 0.88 FFAR1 (0.48) HSD17B2FFAR1
SCHEMBL4969393 0.87 AKR1C3 (0.41) KMT2AFFAR1HDAC1HDAC2
SCHEMBL66968 0.86 L3MBTL1 (0.40) HSD17B2MEN1KMT2AHPGDPDK1
SCHEMBL4970375 0.86 FFAR1 (0.48) HSD17B2MEN1KMT2APOLBHPGD
SCHEMBL4968623 0.86 FFAR1 (0.47) HSD17B2FFAR1NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP disclosed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US disclosed
EP-1781274-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018325-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD HSD17B2 357/4885MEN1 4745/4885KMT2A 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.